Efficacy of low-dose spironolactone on top of angiotensin receptor blockade in patients with glomerulonephritis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yu, Byung Chul | - |
dc.contributor.author | Lee, Min Sung | - |
dc.contributor.author | Moon, Jong Joo | - |
dc.contributor.author | Choi, Soo Jeong | - |
dc.contributor.author | Kim, Jin Kuk | - |
dc.contributor.author | Hwang, Seung Duk | - |
dc.contributor.author | Park, Moo Yong | - |
dc.date.accessioned | 2021-08-11T11:43:50Z | - |
dc.date.available | 2021-08-11T11:43:50Z | - |
dc.date.issued | 2018-09 | - |
dc.identifier.issn | 2211-9132 | - |
dc.identifier.issn | 2211-9140 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/5656 | - |
dc.description.abstract | Background: Previous studies have shown that aldosterone antagonists have a proteinuria-lowering effect in patients with proteinuria and progressive proteinuric disease not adequately controlled by the use of angiotensin receptor blockers (ARBs). Aldosterone antagonists, in combination with ARBs, might improve proteinuria in patients with glomerulonephritis (GN). Methods: In the present retrospective study, we evaluated the proteinuria-lowering effect and drug safety of low-dose spironolactone (12.5 mg/day) in 42 patients with GN being treated with an ARB. Results: Proteinuria decreased from a mean total-protein-to-creatinine (TP/Cr) ratio of 592.3 +/- 42.0 mg/g at baseline to 335.6 +/- 43.3 mg/g after three months of treatment with spironolactone (P < 0.001). After the initial three months, the mean TP/Cr ratio increased progressively at six, nine, and 12 months; however, it was still less than the baseline value (P = 0.001, < 0.001, and < 0.001, respectively). Although serum Cr levels increased significantly at three and nine months compared with baseline (P = 0.036 and 0.026, respectively), there was no time effect of treatment (P = 0.071). Serum potassium levels tended to increase with time (P = 0.118), whereas systolic and diastolic blood pressures decreased with time (P = 0.122 and 0.044, respectively). Conclusion: Low-dose spironolactone in combination with an ARB reduced proteinuria in patients with GN, which could represent a novel treatment option in individuals whose proteinuria is not optimally controlled by the use of ARBs alone. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한신장학회 | - |
dc.title | Efficacy of low-dose spironolactone on top of angiotensin receptor blockade in patients with glomerulonephritis | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.23876/j.krcp.2018.37.3.257 | - |
dc.identifier.scopusid | 2-s2.0-85053533082 | - |
dc.identifier.wosid | 000456124700010 | - |
dc.identifier.bibliographicCitation | Kidney Research and Clinical Practice, v.37, no.3, pp 257 - 265 | - |
dc.citation.title | Kidney Research and Clinical Practice | - |
dc.citation.volume | 37 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 257 | - |
dc.citation.endPage | 265 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002384361 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.subject.keywordPlus | CONVERTING ENZYME-INHIBITION | - |
dc.subject.keywordPlus | ALDOSTERONE BLOCKADE | - |
dc.subject.keywordPlus | IGA NEPHROPATHY | - |
dc.subject.keywordPlus | VASCULAR INJURY | - |
dc.subject.keywordPlus | PROTEINURIA | - |
dc.subject.keywordPlus | ESCAPE | - |
dc.subject.keywordPlus | GLOMERULOSCLEROSIS | - |
dc.subject.keywordPlus | EPLERENONE | - |
dc.subject.keywordPlus | REGRESSION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | Angiotensin receptor antagonists | - |
dc.subject.keywordAuthor | Glomerulonephritis | - |
dc.subject.keywordAuthor | Mineralocorticoid receptor antagonists | - |
dc.subject.keywordAuthor | Proteinuria | - |
dc.subject.keywordAuthor | Spironolactone | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.